fda.gov ยท Apr 30, 2026 02:21 PM UTC

FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List

FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List

Summary

FDA is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound ...

Original reporting

Open original source

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Related coverage